{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:42:22Z","timestamp":1787506942633,"version":"build-2736575974"},"reference-count":87,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.mayocp.2026.03.001","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T11:21:58Z","timestamp":1780658518000},"page":"1185-1201","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma: Mayo Clinic Systematic Management and Risk-Adapted Therapy for Lymphoid Malignancies (lySMART) Consensus Guidelines 2026"],"prefix":"10.1016","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3221-7314","authenticated-orcid":false,"given":"Sameer A.","family":"Parikh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Hampel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey E.","family":"Roeker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yucai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazie","family":"Tsang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Parrondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Bailen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber","family":"Koehler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy L.","family":"Behnken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine C.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talal","family":"Hilal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sikander","family":"Ailawadhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier L.","family":"Munoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison C.","family":"Rosenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asher","family":"Chanan-Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinthya J.","family":"Zepeda-Mendoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca L.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis A.","family":"Hanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"Braggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan L.","family":"Slager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy G.","family":"Call","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose F.","family":"Leis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad S.","family":"Kenderian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil E.","family":"Kay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.mayocp.2026.03.001_bib1","article-title":"Cancer statistics, 2026","volume":"76","author":"Siegel","year":"2026","journal-title":"CA Cancer J Clin"},{"issue":"25","key":"10.1016\/j.mayocp.2026.03.001_bib2","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment and supportive management of chronic lymphocytic leukemia","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.mayocp.2026.03.001_bib3","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.74","article-title":"First-line ibrutinib treatment in patients with chronic lymphocytic leukemia is associated with overall survival rates similar to those of an age-matched general population: a pooled post hoc analysis","volume":"8","author":"Ghia","year":"2024","journal-title":"Hemasphere"},{"issue":"7","key":"10.1016\/j.mayocp.2026.03.001_bib4","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"15","key":"10.1016\/j.mayocp.2026.03.001_bib5","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1182\/blood.2022016279","article-title":"Progression and survival of monoclonal B-cell lymphocytosis (MBL): a screening study of 10,139 individuals","volume":"140","author":"Slager","year":"2022","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.mayocp.2026.03.001_bib6","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1182\/blood-2015-02-585059","article-title":"Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification","volume":"126","author":"Strati","year":"2015","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.mayocp.2026.03.001_bib7","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1053\/j.seminoncol.2016.02.009","article-title":"Prognostic factors and risk stratification in chronic lymphocytic leukemia","volume":"43","author":"Parikh","year":"2016","journal-title":"Semin Oncol"},{"issue":"6","key":"10.1016\/j.mayocp.2026.03.001_bib8","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(16)30029-8","article-title":"An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data","volume":"17","year":"2016","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.mayocp.2026.03.001_bib9","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1182\/blood.2020009813","article-title":"The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL","volume":"138","author":"Parikh","year":"2021","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.mayocp.2026.03.001_bib10","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1182\/blood-2018-09-873083","article-title":"Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact","volume":"133","author":"Baliakas","year":"2019","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.mayocp.2026.03.001_bib11","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.24.00975","article-title":"Ibrutinib in early-stage chronic lymphocytic leukemia: the randomized, placebo-controlled, double-blind, phase III CLL12 trial","volume":"43","author":"Langerbeins","year":"2025","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.mayocp.2026.03.001_bib12","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199805213382104","article-title":"Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia","volume":"338","author":"Dighiero","year":"1998","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.mayocp.2026.03.001_bib13","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/hon.2900060103","article-title":"Treatment of early chronic lymphocytic leukemia: intermittent chlorambucil versus observation","volume":"6","author":"Shustik","year":"1988","journal-title":"Hematol Oncol"},{"issue":"8","key":"10.1016\/j.mayocp.2026.03.001_bib14","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1038\/s41375-020-0747-7","article-title":"Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial","volume":"34","author":"Herling","year":"2020","journal-title":"Leukemia"},{"issue":"14","key":"10.1016\/j.mayocp.2026.03.001_bib15","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1002\/cncr.25853","article-title":"Experience with rituximab immunotherapy as an early intervention in patients with Rai stage 0 to II chronic lymphocytic leukemia","volume":"117","author":"Ferrajoli","year":"2011","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.mayocp.2026.03.001_bib16","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.3109\/10428194.2015.1016932","article-title":"Early treatment of high risk chronic lymphocytic leukemia with alemtuzumab, rituximab and poly-(1-6)-\u03b2-glucotriosyl-(1-3)-\u03b2-glucopyranose beta-glucan is well tolerated and achieves high complete remission rates","volume":"56","author":"Zent","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.mayocp.2026.03.001_bib17","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia","volume":"381","author":"Shanafelt","year":"2019","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.mayocp.2026.03.001_bib18","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N Engl J Med"},{"issue":"10232","key":"10.1016\/j.mayocp.2026.03.001_bib19","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.mayocp.2026.03.001_bib20","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and obinutuzumab in patients with CLL and coexisting conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.mayocp.2026.03.001_bib21","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa2213093","article-title":"First-line venetoclax combinations in chronic lymphocytic leukemia","volume":"388","author":"Eichhorst","year":"2023","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.mayocp.2026.03.001_bib22","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1056\/NEJMoa2409804","article-title":"Fixed-duration acalabrutinib combinations in untreated chronic lymphocytic leukemia","volume":"392","author":"Brown","year":"2025","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.mayocp.2026.03.001_bib23","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S1470-2045(22)00293-5","article-title":"Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial","volume":"23","author":"Tam","year":"2022","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.mayocp.2026.03.001_bib24","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1056\/NEJMoa2504341","article-title":"Measurable residual disease\u2013guided therapy for chronic lymphocytic leukemia","volume":"393","author":"Munir","year":"2025","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.mayocp.2026.03.001_bib25","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa2310063","article-title":"Chronic lymphocytic leukemia therapy guided by measurable residual disease","volume":"390","author":"Munir","year":"2024","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.mayocp.2026.03.001_bib26","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.mayocp.2026.03.001_bib27","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1002\/ajh.27747","article-title":"Comparison of frontline therapies in older adults age \u226580 years with chronic lymphocytic leukemia (CLL): a Mayo Clinic and Danish nation-wide study","volume":"100","author":"Tsang","year":"2025","journal-title":"Am J Hematol"},{"issue":"14","key":"10.1016\/j.mayocp.2026.03.001_bib28","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1182\/bloodadvances.2025015818","article-title":"Venetoclax-based regimens in octogenarian patients with CLL: efficacy, safety, and comparison to BTKi in a multicenter cohort","volume":"9","author":"Serafin","year":"2025","journal-title":"Blood Adv"},{"issue":"suppl 15","key":"10.1016\/j.mayocp.2026.03.001_bib29","doi-asserted-by":"crossref","first-page":"7500","DOI":"10.1200\/JCO.2021.39.15_suppl.7500","article-title":"First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia","volume":"39","author":"Byrd","year":"2021","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.mayocp.2026.03.001_bib30","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.mayocp.2026.03.001_bib31","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.70246","article-title":"Overall survival outcomes with first-line continuous ibrutinib and fixed-duration ibrutinib-venetoclax treatments in patients with chronic lymphocytic leukemia: comparison with an age-matched European population","volume":"9","author":"Ghia","year":"2025","journal-title":"Hemasphere"},{"issue":"18","key":"10.1016\/j.mayocp.2026.03.001_bib32","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1182\/blood.2024028205","article-title":"Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL\/SLL","volume":"146","author":"Burger","year":"2025","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.mayocp.2026.03.001_bib33","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1182\/blood-2023-182397","article-title":"Long-term outcomes in chronic lymphocytic leukemia treated with ibrutinib: 10-year follow-up of a phase 2 study","volume":"142","author":"Itsara","year":"2023","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.mayocp.2026.03.001_bib34","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1182\/blood.2024024476","article-title":"Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN","volume":"146","author":"Sharman","year":"2025","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.mayocp.2026.03.001_bib35","doi-asserted-by":"crossref","first-page":"7011","DOI":"10.1200\/JCO.2025.43.16_suppl.7011","article-title":"SEQUOIA 5-year follow-up in arm C: frontline zanubrutinib monotherapy in patients with del(17p) and treatment-naive chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL)","volume":"43","author":"Tam","year":"2025","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.mayocp.2026.03.001_bib36","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1182\/blood.2024024631","article-title":"Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study","volume":"144","author":"Al-Sawaf","year":"2024","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.mayocp.2026.03.001_bib37","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1056\/NEJMoa2515458","article-title":"Fixed-duration versus continuous treatment for chronic lymphocytic leukemia","volume":"394","author":"Al-Sawaf","year":"2026","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.mayocp.2026.03.001_bib38","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood.2021014488","article-title":"Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort","volume":"139","author":"Tam","year":"2022","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.mayocp.2026.03.001_bib39","doi-asserted-by":"crossref","first-page":"7500","DOI":"10.1200\/JCO.2023.41.16_suppl.7500","article-title":"Results of a phase 3 study of IVO vs IO for previously untreated older patients (pts) with chronic lymphocytic leukemia (CLL) and impact of COVID-19 (Alliance)","volume":"41","author":"Woyach","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.mayocp.2026.03.001_bib40","author":"F\u00fcrstenau","year":"2025"},{"issue":"9","key":"10.1016\/j.mayocp.2026.03.001_bib41","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1001\/jamaoncol.2024.2122","article-title":"Measurable residual disease and clinical outcomes in chronic lymphocytic leukemia: a systematic review and meta-analysis","volume":"10","author":"Rios-Olais","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.mayocp.2026.03.001_bib42","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1200\/JCO.24.01192","article-title":"End Point Surrogacy in First-Line Chronic Lymphocytic Leukemia","volume":"43","author":"Simon","year":"2025","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.mayocp.2026.03.001_bib43","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1200\/JCO.19.03355","article-title":"ASCEND: phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"38","author":"Ghia","year":"2020","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.mayocp.2026.03.001_bib44","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.mayocp.2026.03.001_bib45","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1016\/S2352-3026(22)00320-9","article-title":"Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study","volume":"10","author":"Shadman","year":"2023","journal-title":"Lancet Haematol"},{"issue":"9","key":"10.1016\/j.mayocp.2026.03.001_bib46","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.3324\/haematol.2020.272500","article-title":"Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed\/refractory chronic lymphocytic leukemia","volume":"106","author":"Rogers","year":"2021","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.mayocp.2026.03.001_bib47","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1182\/blood.2021014960","article-title":"Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial","volume":"140","author":"Shanafelt","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.mayocp.2026.03.001_bib48","doi-asserted-by":"crossref","first-page":"4629","DOI":"10.1182\/blood-2024-199676","article-title":"Outcomes of patients with chronic lymphocytic leukemia discontinuing Bruton tyrosine kinase inhibitors due to adverse effects","volume":"144","author":"Mansour","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.mayocp.2026.03.001_bib49","first-page":"92","article-title":"Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor\u2013intolerant patients with B-cell malignancies: results of the phase I\/II BRUIN trial","volume":"110","author":"Shah","year":"2025","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.mayocp.2026.03.001_bib50","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/s41408-022-00721-6","article-title":"Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib","volume":"12","author":"Hampel","year":"2022","journal-title":"Blood Cancer J"},{"issue":"10","key":"10.1016\/j.mayocp.2026.03.001_bib51","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1182\/blood.2023023659","article-title":"Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib","volume":"144","author":"Woyach","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.mayocp.2026.03.001_bib52","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1470-2045(17)30909-9","article-title":"Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial","volume":"19","author":"Jones","year":"2018","journal-title":"Lancet Oncol"},{"issue":"suppl 1","key":"10.1016\/j.mayocp.2026.03.001_bib53","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1182\/blood-2024-198200","article-title":"Outcomes with venetoclax-based treatment in patients with covalent Bruton tyrosine kinase inhibitor (cBTKi)\u2013treated, chemotherapy-na\u00efve chronic lymphocytic leukemia (CLL): an international retrospective study","volume":"144","author":"Hampel","year":"2024","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.mayocp.2026.03.001_bib54","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/ajh.27563","article-title":"Treatment effectiveness of venetoclax-based therapy after Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia: an international real-world study","volume":"100","author":"Ghosh","year":"2025","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.mayocp.2026.03.001_bib55","doi-asserted-by":"crossref","first-page":"E57","DOI":"10.1002\/ajh.25690","article-title":"Addition of venetoclax at time of progression in ibrutinib-treated patients with chronic lymphocytic leukemia: combination therapy to prevent ibrutinib flare","volume":"95","author":"Hampel","year":"2020","journal-title":"Am J Hematol"},{"issue":"22","key":"10.1016\/j.mayocp.2026.03.001_bib56","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1200\/JCO-25-00166","article-title":"Phase III trial of pirtobrutinib versus idelalisib\/rituximab or bendamustine\/rituximab in covalent Bruton tyrosine kinase inhibitor\u2013pretreated chronic lymphocytic leukemia\/small lymphocytic lymphoma (BRUIN CLL-321)","volume":"43","author":"Sharman","year":"2025","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.mayocp.2026.03.001_bib57","doi-asserted-by":"crossref","first-page":"4553","DOI":"10.1182\/bloodadvances.2022007812","article-title":"Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen","volume":"6","author":"Thompson","year":"2022","journal-title":"Blood Adv"},{"issue":"23","key":"10.1016\/j.mayocp.2026.03.001_bib58","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1182\/blood.2024025525","article-title":"The MURANO study: final analysis and retreatment\/crossover substudy results of VenR for patients with relapsed\/refractory CLL","volume":"145","author":"Kater","year":"2025","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.mayocp.2026.03.001_bib59","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1038\/s41375-025-02662-y","article-title":"Resistance to targeted therapies in chronic lymphocytic leukemia: current status and perspectives for clinical and diagnostic practice","volume":"39","author":"Blombery","year":"2025","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.mayocp.2026.03.001_bib60","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2300696","article-title":"Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia","volume":"389","author":"Mato","year":"2023","journal-title":"N Engl J Med"},{"issue":"10402","key":"10.1016\/j.mayocp.2026.03.001_bib61","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(23)01052-8","article-title":"Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study","volume":"402","author":"Siddiqi","year":"2023","journal-title":"Lancet"},{"issue":"suppl 1","key":"10.1016\/j.mayocp.2026.03.001_bib62","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1182\/blood-2024-199708","article-title":"Epcoritamab monotherapy in patients (pts) with relapsed or refractory (R\/R) chronic lymphocytic leukemia (CLL): results from CLL expansion and optimization cohorts of EPCORE CLL-1","volume":"144","author":"Danilov","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.mayocp.2026.03.001_bib63","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1182\/blood-2024-194839","article-title":"Efficacy and safety of the Bruton's tyrosine kinase (BTK) degrader NX-5948 in patients with relapsed\/refractory (R\/R) chronic lymphocytic leukemia (CLL): updated results from an ongoing phase 1a\/b Study","volume":"144","author":"Shah","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.mayocp.2026.03.001_bib64","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1182\/blood-2024-199116","article-title":"Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma: results from the phase 1 CaDAnCe-101 Study","volume":"144","author":"Thompson","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.mayocp.2026.03.001_bib65","series-title":"Updated efficacy and safety of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients (pts) with relapsed or refractory (R\/R) CLL\/SLL: results from the ongoing phase (PH) 1 CaDAnCe-101 study","author":"Scarfo","year":"2025"},{"issue":"14","key":"10.1016\/j.mayocp.2026.03.001_bib66","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1182\/bloodadvances.2020003726","article-title":"Reduced-intensity conditioning hematopoietic stem cell transplantation for chronic lymphocytic leukemia and Richter's transformation","volume":"5","author":"Lahoud","year":"2021","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.mayocp.2026.03.001_bib67","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.3324\/haematol.2019.240564","article-title":"The role of 18F-FDG-PET in detecting Richter's transformation of chronic lymphocytic leukemia in patients receiving therapy with a B-cell receptor inhibitor","volume":"105","author":"Wang","year":"2020","journal-title":"Haematologica"},{"issue":"suppl 3","key":"10.1016\/j.mayocp.2026.03.001_bib68","first-page":"e73","article-title":"73 | Primary endpoint evaluation of a multicenter phase 2 study of venetoclax in combination with R-CHOP (VR-CHOP) for patients with Richter syndrome","volume":"43","author":"Davids","year":"2025","journal-title":"Hematol Oncol"},{"issue":"4","key":"10.1016\/j.mayocp.2026.03.001_bib69","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.mayocp.2026.03.001_bib70","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/s41591-023-02722-9","article-title":"Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial","volume":"30","author":"Al-Sawaf","year":"2024","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.mayocp.2026.03.001_bib71","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/S1470-2045(24)00396-6","article-title":"Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial","volume":"25","author":"Tedeschi","year":"2024","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.mayocp.2026.03.001_bib72","doi-asserted-by":"crossref","first-page":"e682","DOI":"10.1016\/S2352-3026(24)00172-8","article-title":"Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1\/2 BRUIN study","volume":"11","author":"Wierda","year":"2024","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.mayocp.2026.03.001_bib73","series-title":"Single-agent epcoritamab leads to deep responses in patients (pts) with Richter\u2019s transformation (RT): primary results from the EPCORE CLL-1 trial","author":"Kater","year":"2024"},{"issue":"17","key":"10.1016\/j.mayocp.2026.03.001_bib74","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1200\/JCO.24.00033","article-title":"Anti-CD19 chimeric antigen receptor T-cell therapy for Richter transformation: an international, multicenter, retrospective study","volume":"42","author":"Kittai","year":"2024","journal-title":"J Clin Oncol"},{"issue":"suppl 3","key":"10.1016\/j.mayocp.2026.03.001_bib75","first-page":"e143","article-title":"143 | Real-world outcomes of axicabtagene ciloleucel (axi-cel) for the treatment of Richter transformation to large B-cell lymphoma (RT-LBCL)","volume":"43","author":"Winter","year":"2025","journal-title":"Hematol Oncol"},{"issue":"11","key":"10.1016\/j.mayocp.2026.03.001_bib76","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.3324\/haematol.2020.256388","article-title":"Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaboration","volume":"106","author":"Stephens","year":"2021","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.mayocp.2026.03.001_bib77","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41408-022-00616-6","article-title":"Chronic lymphocytic leukemia (CLL) with Reed-Sternberg\u2013like cells vs classic Hodgkin lymphoma transformation of CLL: does this distinction matter?","volume":"12","author":"King","year":"2022","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.mayocp.2026.03.001_bib78","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11899-017-0366-1","article-title":"A concise review of autoimmune cytopenias in chronic lymphocytic leukemia","volume":"12","author":"Tsang","year":"2017","journal-title":"Curr Hematol Malig Rep"},{"issue":"14","key":"10.1016\/j.mayocp.2026.03.001_bib79","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1056\/NEJMoa2027760","article-title":"Sutimlimab in cold agglutinin disease","volume":"384","author":"Roth","year":"2021","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.mayocp.2026.03.001_bib80","doi-asserted-by":"crossref","first-page":"4169","DOI":"10.1182\/blood.V126.23.4169.4169","article-title":"Pure red cell aplasia (PRCA) in chronic lymphocytic leukemia (CLL): etiology, therapy, and outcomes","volume":"126","author":"Tsang","year":"2015","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.mayocp.2026.03.001_bib81","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jaad.2014.10.028","article-title":"Increased incidence and recurrence rates of nonmelanoma skin cancer in patients with non-Hodgkin lymphoma: a Rochester Epidemiology Project population-based study in Minnesota","volume":"72","author":"Brewer","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.mayocp.2026.03.001_bib82","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1200\/JCO.2012.43.4449","article-title":"Overall and cancer-specific survival of patients with breast, colon, kidney, and lung cancers with and without chronic lymphocytic leukemia: a SEER population-based study","volume":"31","author":"Solomon","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.mayocp.2026.03.001_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2024.101180","article-title":"Prevention and management of infectious complications in patients with chronic lymphocytic leukemia (CLL) treated with BTK and BCL-2 inhibitors, focus on current guidelines","volume":"65","author":"Mikulska","year":"2024","journal-title":"Blood Rev"},{"issue":"1","key":"10.1016\/j.mayocp.2026.03.001_bib84","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/leu.2012.187","article-title":"Infectious complications among individuals with clinical monoclonal B-cell lymphocytosis (MBL): a cohort study of newly diagnosed cases compared to controls","volume":"27","author":"Moreira","year":"2013","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.mayocp.2026.03.001_bib85","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/leu.2015.235","article-title":"Risk of non-hematologic cancer in individuals with high count monoclonal B-cell lymphocytosis (MBL)","volume":"30","author":"Solomon","year":"2016","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.mayocp.2026.03.001_bib86","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/s41375-020-0799-8","article-title":"Risk of serious infection among individuals with and without low count monoclonal B-cell lymphocytosis (MBL)","volume":"35","author":"Shanafelt","year":"2021","journal-title":"Leukemia"},{"issue":"35","key":"10.1016\/j.mayocp.2026.03.001_bib87","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.1200\/JCO.24.00332","article-title":"Risk of incident melanoma among individuals with low-count monoclonal B-cell lymphocytosis","volume":"42","author":"Vallejo","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619626184031?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619626184031?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T11:23:51Z","timestamp":1782905031000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619626184031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":87,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0025619626184031"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2026.03.001","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma: Mayo Clinic Systematic Management and Risk-Adapted Therapy for Lymphoid Malignancies (lySMART) Consensus Guidelines 2026","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2026.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}